June 15, 2020 / 3:40 PM / 2 months ago

German vaccine developer CureVac plans U.S. listing: report

BERLIN (Reuters) - German vaccine maker CureVac plans to raise funds by selling stock in an initial public offering in the United States, Die Welt newspaper reported on Monday, citing finance ministry documents.

A spokesman for CureVac declined to comment on the report, which said the listing would take place on the Nasdaq.

The German government plans to take a stake of about 23% in unlisted CureVac by backing a 300 million euro ($337 million) capital increase to fund the biotech company’s further development of a COVID-19 vaccine.

Reporting by Joseph Nasr; Editing by Scot W. Stevenson

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below